Pharmaceutical News

RSS

Physician panel to discuss issues related to Qutenza at Investor Day

NeurogesX, Inc., a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced today that Anthony DiTonno, President and CEO, and members of the NeurogesX management team, will host an Investor Day on Friday, April 30, 2010, from 8:15am-11:00am EDT in New York City

24 Apr 2010

New research project to make anti-malarial drugs more affordable in Third World countries

Dr Geoff Brown, from the University of Reading's Department of Chemistry, is beginning a £400,000 project that could prove vital for the developing world in its ongoing fight against malaria. His research aims to make anti-malarial drugs more affordable in Third World countries where more than 1.5 million people die of the disease every year.

24 Apr 2010

Immunization campaigns to be launched simultaneously in 112 countries and territories

For the first time, immunization campaigns are being launched simultaneously tomorrow in 112 countries and territories in the World Health Organization Regions of the Americas, Eastern Mediterranean and Europe, with the goals of expanding immunization coverage and raising awareness of the importance of vaccines.

24 Apr 2010

AFREZZA Inhalation Powder reduces incidence of hypoglycemia in patients with Type 1 diabetes

Diabetes treatment regimens containing AFREZZATM (insulin human [rDNA origin]) Inhalation Powder, a well-tolerated, ultra rapid acting insulin, provide glucose control similar to standard insulin therapy along with weight loss and reduced incidence of hypoglycemia in patients with Type 1 diabetes and poorly controlled blood sugar levels, according to a two-year study presented today at the American Association of Clinical Endocrinologists 19th Annual Meeting (Poster #283).

24 Apr 2010

New Jersey District Court jury finds Nycomed's U.S. Patent No. 4,758,579 not invalid: Teva

Teva Pharmaceutical Industries Ltd. announced today that a jury returned a verdict in the U.S. District Court for the District of New Jersey finding that Nycomed's U.S. Patent No. 4,758,579 is not invalid. The Court has reserved decision on the issue of what, if any, effect to give to the jury's determinations in connection with the obviousness-type double patenting defenses, which Teva has argued is to be decided by the Court.

24 Apr 2010

Victoza produces greater reductions in A1C, FPG and body weight than Januvia: Study

Yesterday, The Lancet published online the results of the first study comparing the once-daily human GLP-1 analog, Victoza (liraglutide [rDNA] injection) with a DPP-4 inhibitor, Januvia. The 26-week trial showed that Victoza produced significantly greater reductions in A1C, fasting plasma glucose, and body weight than Januvia, with similar or better overall treatment satisfaction.

24 Apr 2010

Federal officials confirm a shift in Medicaid drug rebates

Kaiser Health News staff writer Christopher Weaver writes: "The federal agency that oversees Medicaid confirmed Thursday that some money states receive as rebates from drugmakers will now be redirected to the federal government to help pay for the new health overhaul" (Weaver, 4/22).

24 Apr 2010

Merz Aesthetics debuts at ASAPS annual meeting with announcement of FDA approval of Asclera Injection

Following news of the acquisition of BioForm Medical, Inc. earlier this year, Merz Aesthetics, the new business unit of Merz Pharma Group, makes its debut at the prestigious American Society of Aesthetic Plastic Surgeons (ASAPS) annual meeting with the announcement of the U.S. Food and Drug Administration's (FDA) recent approval of Asclera™ (polidocanol) Injection, a sclerotherapy treatment for uncomplicated spider and reticular veins.

24 Apr 2010

Cipher Pharmaceuticals' first-quarter total revenue up 52%

Cipher Pharmaceuticals Inc. today announced its financial and operational results for the three months ended March 31, 2010.

23 Apr 2010

MicroStockProfit.com releases investment report on ANX

MicroStockProfit.com announces an investment report featuring ADVENTRX Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

23 Apr 2010

Plant-based vaccine factory to produce vaccines and therapeutics within weeks of outbreaks

The Fraunhofer Center for Molecular Biotechnology in Newark, Delaware, the Fraunhofer Center for Manufacturing Innovation in Boston, Massachusetts, the Boston University College of Engineering, and the biopharmaceutical company iBio, Inc. in Newark, Delaware, announced today that they have developed a fully automated, scalable "factory" that uses natural (non-genetically-modified) green plants to efficiently produce large quantities of vaccines and therapeutics within weeks.

23 Apr 2010

GenVec's 2009 revenues down 8%: MicroStockProfit.com

MicroStockProfit.com announces an investment report featuring GenVec Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

23 Apr 2010

MMV supports Pfizer's AZCQ clinical trial for intermittent preventive treatment of malaria in pregnant women

Pfizer Inc. and Medicines for Malaria Venture (MMV) entered into an agreement for the development, access and delivery of a fixed-dose combination treatment consisting of azithromycin dihydrate (AZ) and chloroquine phosphate (CQ) for the Intermittent Preventive Treatment of P. falciparum malaria in pregnancy (IPTp). There is currently an unmet need for new treatment options and the World Health Organization (WHO) estimates that some 30 million pregnant women are at risk for malaria in endemic areas in Africa each year.

23 Apr 2010

Genmab reaches milestone for Arzerra under terms of collaboration with GSK

Genmab A/S announced today it has reached a milestone for Arzerra(ofatumumab) under the terms of its collaboration with GlaxoSmithKline.

23 Apr 2010

Report on Canadian spending trends in prescribed and non-prescribed drugs

Total drug spending in Canada is estimated to have reached $30.0 billion in 2009, about $1.5 billion more than in 2008, according to a new report released today by the Canadian Institute for Health Information (CIHI). This represents an estimated increase of 5.1%, the lowest annual growth rate observed in more than a decade.

23 Apr 2010

New multi-faceted treatment program for young adults addicted to opioid drugs

A multi-faceted treatment program for young adults addicted to opioid drugs was unveiled today at the National Institute on Drug Abuse's Blending Conference in Albuquerque, N.M. This eighth meeting in the series brings together researchers and clinicians so their latest findings can be immediately applied to the needs of patients and their families dealing with addictive disorders.

23 Apr 2010

Geron scientists highlight importance of telomerase inhibitor, GRN163L at AACR 2010

Geron Corporation today announced five presentations by Geron scientists and collaborators on the company's telomerase inhibitor, imetelstat sodium, including the drug's activity against cancer stem cells, at the 101st American Association for Cancer Research annual meeting held in Washington D.C.

23 Apr 2010

CAPS launches new service for admixture and delivery of Hibernation Therapeutics' Adenocaine microplegia

Central Admixture Pharmacy Services, Inc. (CAPS®), a B. Braun company, announced today the launch of its newest service for the admixture and delivery of Hibernation Therapeutics' patented Adenocaine™ microplegia, the world's first low-potassium, non-depolarizing cardioplegia solution.

From B. Braun Melsungen AG 23 Apr 2010

pHase Pharmaceuticals launches new drug development company

pHase Pharmaceuticals, LLC announces the launch of its new drug development company. pHase Pharmaceuticals is led by a cohesive team of drug development experts who have extensive experience bringing new drugs to market and garnering FDA approval.

23 Apr 2010

Genentech submits sBLA for Herceptin plus chemotherapy for advanced HER2-positive stomach cancer

Genentech, Inc., a wholly owned member of the Roche Group, announced today that the company submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for Herceptin® (trastuzumab) plus chemotherapy in people with advanced, HER2-positive adenocarcinoma of the stomach, including gastroesophageal junction cancer.

23 Apr 2010

Pharmaceutical News

Physician panel to discuss issues related to Qutenza at Investor Day

New research project to make anti-malarial drugs more affordable in Third World countries

Immunization campaigns to be launched simultaneously in 112 countries and territories

AFREZZA Inhalation Powder reduces incidence of hypoglycemia in patients with Type 1 diabetes

New Jersey District Court jury finds Nycomed's U.S. Patent No. 4,758,579 not invalid: Teva

Victoza produces greater reductions in A1C, FPG and body weight than Januvia: Study

Federal officials confirm a shift in Medicaid drug rebates

Merz Aesthetics debuts at ASAPS annual meeting with announcement of FDA approval of Asclera Injection

Cipher Pharmaceuticals' first-quarter total revenue up 52%

MicroStockProfit.com releases investment report on ANX

Plant-based vaccine factory to produce vaccines and therapeutics within weeks of outbreaks

GenVec's 2009 revenues down 8%: MicroStockProfit.com

MMV supports Pfizer's AZCQ clinical trial for intermittent preventive treatment of malaria in pregnant women

Genmab reaches milestone for Arzerra under terms of collaboration with GSK

Report on Canadian spending trends in prescribed and non-prescribed drugs

New multi-faceted treatment program for young adults addicted to opioid drugs

Geron scientists highlight importance of telomerase inhibitor, GRN163L at AACR 2010

CAPS launches new service for admixture and delivery of Hibernation Therapeutics' Adenocaine microplegia

pHase Pharmaceuticals launches new drug development company

Genentech submits sBLA for Herceptin plus chemotherapy for advanced HER2-positive stomach cancer

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News